SCHEMBL6323660

SCHEMBL6323660

CCCCCc1ccc(S(=O)(=O)N(C)CC(C)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.51
ALDH1A1 P00352 3/20 0.49
CNR2 P34972 1/20 0.46
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
THRA P10827 2/20 0.44
THRB P10828 2/20 0.44
STAT3 P40763 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
HSD17B10 Q99714 2/20 0.43
HPGD P15428 1/20 0.43
CCR5 P51681 1/20 0.43
RARB P10826 2/20 0.42
S1PR2 O95136 1/20 0.42
S1PR1 P21453 1/20 0.42
S1PR3 Q99500 1/20 0.42
HAO1 Q9UJM8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330926 0.86 ADAM17 (0.53) CA2ALDH1A1CNR2KEAP1NFE2L2
SCHEMBL6328877 0.82 CA2 (0.45) CA2ALDH1A1CNR2KEAP1NFE2L2
SCHEMBL7863071 0.80 CA2 (0.54) CA2ALDH1A1CNR2KEAP1NFE2L2
SCHEMBL6322460 0.78 MMP3 (0.46) CA2KEAP1NFE2L2THRBCA12
SCHEMBL6323645 0.78 CA2 (0.51) CA2ALDH1A1CNR2KEAP1NFE2L2
SCHEMBL6323652 0.78 CA2 (0.51) CA2ALDH1A1CNR2KEAP1NFE2L2
SCHEMBL7856535 0.77 CA2 (0.62) CA2ALDH1A1CNR2SMN1; SMN2THRA
SCHEMBL6321482 0.77 ESR1 (0.53) THRBCCR5ESR1KDM4ELMNA
SCHEMBL12040860 0.77 CA2 (0.62) CA2ALDH1A1CNR2SMN1; SMN2THRA
SCHEMBL6325888 0.76 KMT2A (0.51) ALDH1A1SMN1; SMN2HSD17B10HPGDCCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed
EP-0939629-A4 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO CO (US) 2002-07-17 EP disclosed
EP-0939629-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1999-09-08 EP disclosed
WO-1998003166-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1998-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 CA2 492/4885ALDH1A1 986/4885CNR2 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.